Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
FIGX
STRONG SELLREMOVEFIGX Capital Acquisition Corp. · Financial Services · United States · $198M · Avg Vol: $411K/d
FIGX Capital Acquisition is a special purpose acquisition company (SPAC). It has no operating business, no moat, and represents a speculative vehicle that completely violates our quality compounding philosophy.
COMPANY DESCRIPTION
FIGX Capital Acquisition Corp. is a Special Purpose Acquisition Company (SPAC) formed to effect a business combination such as a merger, share exchange, or asset acquisition. It offers investors an opportunity to participate in a de-SPAC transaction, relying on its management team's expertise to identify a suitable private target company. This shell company's value is tied to its ability to successfully identify and acquire an operating business.
FINANCIAL SUMMARY (USD)
| Year | 2025 |
|---|---|
| Revenue | — |
| EPS | — |
| Shares | 19M |
| Debt | 7M |
| Equity | 148M |
| Op CF | — |
| Inv CF | — |
| Fin CF | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Financial Services, ranked by industry match, size, and score similarity. Cross-listings of FIGX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| FIGX | FIGX Capital Acquisition Corp.(you) | $198M | 17 | STRONG SELL |
| EGHA | EGH Acquisition Corp. | $212M | 16 | STRONG SELL |
| GSHR | Gesher Acquisition Corp. II | $213M | 19 | STRONG SELL |
| DAAQ | Digital Asset Acquisition Corp. | $237M | 15 | STRONG SELL |
| TDAC | Translational Development Acquisition Corp. | $236M | 14 | STRONG SELL |
| MACI | Melar Acquisition Corp. I | $234M | 13 | STRONG SELL |
| DMAA | Drugs Made In America Acquisition Corp. | $257M | 15 | STRONG SELL |
| RAAQ | Real Asset Acquisition Corp. | $262M | 15 | STRONG SELL |
| BACC | Blue Acquisition Corp. | $291M | 17 | STRONG SELL |
| PLMK | Plum Acquisition Corp. IV | $258M | 14 | STRONG SELL |
Peer medians: ROE 10.8% · P/E 13.6x · Gross margin 0.0%